EN DE
Watch Xlife Sciences AG for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Xlife Sciences AG (XLS) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Xlife Sciences AG stock CHF 9.08, price CHF 8.42, upside +7.8%, quality 27 out of 100. Rating: fairly valued. Calculated from audited financials with 2 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare CH · ISIN CH0461929603

XS Xlife Sciences AG logo Thin data Nov 9, 2026

Xlife Sciences AG

XLS · SW
Fairly valued, weak quality

The stock costs about what our calculation considers fair.

Low debt
Last quarter vs. a year ago: revenue +34%, profit +95%.
Fair value CHF 9.08 · Fairly valued
Mixed Growth (revenue 5y −7.1 %/yr in CHF)
Mixed vs. peers (4/7)
Quality 27/100
Negative free cash flow
Narrow moat 9/100
Thin data
Watch Xlife Sciences AG for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

CHF 52.00 CHF 8.42 Fair Value CHF 9.08 Feb 2022 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.

How to read this chart

57‑month range CHF 8.42 – CHF 52.00 · fair‑value band CHF 4.82 – CHF 16.21 · the CHF 8.42 price screens below the CHF 9.08 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.

Follow Xlife Sciences in your weekly email

Every Wednesday you see whether Xlife Sciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Xlife Sciences AG focuses on the development and commercialization of research projects in the life sciences sector.

Show moreShow less

The company's project covers technology platforms, biotechnology/therapies, medical technology, and artificial intelligence/digital health areas that focuses on identifying new therapeutic approaches and biomarkers for common diseases based on human genetic data.

It also produces, researches, develops, and manufactures the chemical and active pharmaceutical ingredients for human and veterinary medicines; and offers clinical research organization services.

In addition, the company builds a bridge between research/ development and healthcare markets, as well as support researchers and entrepreneurs in the positioning, structuring, development, and implementation of their ideas; and operates as an active ingredient manufacturer.

Further, it focuses on identifying innovative biomarkers in the field of kidney diseases; the development of antibody-drug conjugates through a click chemistry approach and microfluidic screening of functional antibodies; and provides Neuromex, a screening instrument for the early-stage detection of neurological diseases.

Xlife Sciences AG was founded in 2019 and is headquartered in Zurich, Switzerland.

Stock analysis

Xlife Sciences AG (XLS) currently trades at CHF 8.42, while our model-based Fair Value estimate is CHF 9.08, so the stock looks roughly fairly valued today (gap 7.3%).

Show more

Valuation

How firm this estimate is: it rests on 2 models at a data quality of 81/100, which puts the data coverage at low.

Scenario range: CHF 4.82 (bear) to CHF 16.21 (bull), the price of CHF 8.42 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 27/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Spin-off in 2020: revenue and profit before it include the divested business. Growth is measured afresh from 2020.

Xlife Sciences AG reported revenue of CHF 275K in FY2025 versus CHF 806K in FY2021, a compound −23.6%/yr. Reported net income was −CHF 21.5M in FY2025.

Key figures

Market cap CHF 48.6M Micro · EPS (TTM) CHF −32.31 · Return on equity −64.1% · Return on assets (EBIT) −3.8% (5-year average) · Operating margin −1,963% · Revenue (TTM) CHF 397K · Revenue growth (YoY) +34.4% · EPS growth (YoY) +94.7%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (medium confidence).

What moves the price

The share trades about 68% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 8%, XLS screens richer than that median.

Fair Value models

Bear CHF 4.82 Fair Value CHF 9.08 Bull CHF 16.21
Price CHF 8.42 · Upside +7.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Owner Earnings CHF 4.82 CHF 9.08 CHF 16.21 73
NCAV (Graham) CHF 2.85 CHF 3.82 CHF 5.70 54
All 2 models by family
DCF Models
Owner Earnings CHF 4.82 CHF 9.08 CHF 16.21 73
Asset-Based
NCAV (Graham) CHF 2.85 CHF 3.82 CHF 5.70 54

Open the full fair value analysis →

Quality Score breakdown

Overall quality 27/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 1
How much profit the company makes from its sales and capital
Quality Growth 10
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 43
Debt, balance sheet and risk of trouble
Investment 52
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 0
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 77
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 55/100
Spin-off in 2020: revenue and profit before it include the divested business. Growth is measured afresh from 2020.
Revenue growth 1 year
−67.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−35.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−7.1%
Start year 2020 (pandemic)
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−779.5% (2020) → −11,462.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch XLS, get fair value alerts →

Compare Xlife Sciences AG with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks

Beats the industry median on 4/6 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 27 · Bottom 25%
Fair Value upside +7.8% · Top 25%
Profitability
Return on assets −4.2% · Above median
Growth and dividend
Revenue growth (quarter YoY) 34.4% · Top 25%
Balance sheet
Debt / equity 0.19× · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.17× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)44 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)91 · sector 97
DIVIDEND (yield)0 · sector 22

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs XLS
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs XLS
Vertex Pharmaceuticals Incorporated VRTX $547.09 $601.80 +10% vs XLS
Samsung Biologics Co 207940 1,516,000 KRW 1,667,600 KRW +10% vs XLS
Genmab A/S GMAB kr 3,527 kr 3,880 +10% vs XLS
WuXi Biologics (Cayman) Inc 2269 HK$47.62 HK$52.38 +10% vs XLS
argenx SE ARGX $927.21 $908.40 −2% vs XLS
CSL Limited CSL A$200.77 A$183.04 −9% vs XLS
Celltrion, Inc 068270 211,000 KRW 74,945 KRW −64% vs XLS
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs XLS

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Xlife Sciences AG: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Xlife Sciences AG Fair Value". https://www.fairvalue-calculator.com/stock/XLS

Frequently asked questions

Is Xlife Sciences AG (XLS) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of CHF 9.08 versus a price of CHF 8.42, about +8% upside (fairly valued).
What is the fair value of XLS?
Our model-based fair value for Xlife Sciences AG is CHF 9.08 (as of Nov 9, 2026), built from audited fundamentals. The current price: CHF 8.42.
What is the quality score of XLS?
Xlife Sciences AG has a Quality Score of 27/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Xlife Sciences AG (XLS)?
Our model-based price target is the fair value of CHF 9.08 (as of Nov 9, 2026) from 2 valuation models. Cautious scenario CHF 4.82, optimistic scenario CHF 16.21. It is a calculation from audited fundamentals, not an analyst target.
What is the Xlife Sciences AG stock forecast for 2026?
Our models put fair value at CHF 9.08, about +8% upside versus a price of CHF 8.42 (fairly valued). Cautious scenario CHF 4.82, optimistic scenario CHF 16.21. The calculation is refreshed regularly with new filings.
What is the revenue of Xlife Sciences AG (XLS)?
Xlife Sciences AG reported trailing-twelve-month revenue of about CHF 397K (latest available figure, as of Nov 9, 2026).
What is the intrinsic value of Xlife Sciences AG (XLS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Xlife Sciences AG it is CHF 9.08 per share (as of Nov 9, 2026), against a price of CHF 8.42. It is the blended result of 2 valuation models in 2 families (DCF Models, Asset-Based).
Is Xlife Sciences AG stock overvalued or undervalued in 2026?
As of Nov 9, 2026, XLS trades below its calculated fair value: price CHF 8.42, fair value CHF 9.08, a gap of about +8% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of XLS?
No. The price is what the market pays today (CHF 8.42); the fair value is what the company's own numbers justify (CHF 9.08). For Xlife Sciences AG the two are CHF 0.6600 per share apart. That gap is exactly why we show both numbers side by side.
How much is Xlife Sciences AG worth?
The market values Xlife Sciences AG at about CHF 48.6M (market capitalisation, as of Nov 9, 2026). Per share that is CHF 8.42; our models calculate a fair value of CHF 9.08 per share.
What do the bullish and bearish scenarios say about XLS?
Our models span a range for Xlife Sciences AG: cautious scenario CHF 4.82, base CHF 9.08, optimistic CHF 16.21 per share (as of Nov 9, 2026, price CHF 8.42). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Xlife Sciences AG (XLS)?
Balance-sheet figures for Xlife Sciences AG (as of Nov 9, 2026): return on equity −64.1%, debt of 0.19 per unit of equity. They feed the Quality Score of 27/100, which measures business quality independently of the share price.
How far is XLS from its 52-week high?
Xlife Sciences AG trades at CHF 8.42, about 68% below its 52-week high of CHF 26.00 and at the low of CHF 8.42 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of CHF 9.08 is for.
Which stocks are comparable to Xlife Sciences AG?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Xlife Sciences AG stock attractive at the current price?
The data as of Nov 9, 2026: price CHF 8.42, calculated fair value CHF 9.08 (+8%), Quality Score 27/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of XLS calculated?
We run Xlife Sciences AG through 2 models from 2 families: DCF Models, Asset-Based. Every model gets the same audited fundamentals; the fair value of CHF 9.08 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Xlife Sciences AG currently trades 7% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Xlife Sciences AG (XLS)?
The closing price on Nov 6, 2026 was CHF 8.42. Our model-based fair value is CHF 9.08, about +8% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Xlife Sciences AG right now?
The model range is unusually wide (CHF 4.82 to CHF 16.21). The outcome hinges heavily on assumptions, so read the point estimate with caution. The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Xlife Sciences AG

How large is the market capitalisation of Xlife Sciences AG (XLS)?
The market capitalisation of Xlife Sciences AG is CHF 48.6M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Xlife Sciences AG (XLS)?
Earnings per share at Xlife Sciences AG are CHF −32.31. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Xlife Sciences AG (XLS)?
The return on equity (ROE) of Xlife Sciences AG is −64.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Xlife Sciences AG (XLS)?
On an EBIT basis the return on assets of Xlife Sciences AG is −3.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Xlife Sciences AG (XLS)?
The operating margin of Xlife Sciences AG is −1,963% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Xlife Sciences AG (XLS)?
Revenue at Xlife Sciences AG is growing +34.4% versus a year earlier (3y avg −35.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Xlife Sciences AG (XLS)?
Earnings per share at Xlife Sciences AG are growing +94.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Xlife Sciences AG (XLS) generate?
The free cash flow of Xlife Sciences AG is −CHF 1.3M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Xlife Sciences AG (XLS) carry?
The net debt of Xlife Sciences AG is CHF 59.5M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Xlife Sciences AG in the live analysis

One click puts Xlife Sciences AG on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.